Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma. Adults with newly diagnosed disease and Karnofsky performance status (KPS) ≥ 60 were enrolled. Treatment was started within 5 weeks a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Butowski, Nicholas, Chang, Susan M., Lamborn, Kathleen R., Polley, Mei–Yin, Pieper, Russell, Costello, Joseph F., Vandenberg, Scott, Parvataneni, Rupa, Nicole, Angelina, Sneed, Patricia K., Clarke, Jennifer, Hsieh, Emily, Costa, Bruno M., Reis, Rui M., Hristova-Kazmierski, Maria, Nicol, Steven J., Thornton, Donald E., Prados, Michael D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2011
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3223090/
https://ncbi.nlm.nih.gov/pubmed/21896554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor130
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller